Filtros de búsqueda

Lista de obras de Grant McArthur

18F-FLT PET as a surrogate marker of drug efficacy during mTOR inhibition by everolimus in a preclinical cisplatin-resistant ovarian tumor model

artículo científico publicado en 2010

A First-Time-In-Human Phase I Clinical Trial of Bispecific Antibody-Targeted, Paclitaxel-Packaged Bacterial Minicells

artículo científico publicado en 2015

A community-based model of rapid autopsy in end-stage cancer patients

artículo científico publicado en 2016

A multisite blinded study for the detection of BRAF mutations in formalin-fixed, paraffin-embedded malignant melanoma

artículo científico publicado en 2013

A novel compound which sensitizes BRAF wild-type melanoma cells to vemurafenib in a TRIM16-dependent manner

artículo científico publicado en 2016

A phase I study to determine the safety, pharmacokinetics and pharmacodynamics of a dual VEGFR and FGFR inhibitor, brivanib, in patients with advanced or metastatic solid tumors

artículo científico publicado en 2010

A phase I trial of imatinib in combination with mFOLFOX6-bevacizumab in patients with advanced colorectal cancer

artículo científico publicado en 2012

AKT promotes rRNA synthesis and cooperates with c-MYC to stimulate ribosome biogenesis in cancer

artículo científico publicado en 2011

AKT signalling is required for ribosomal RNA synthesis and progression of Eμ-Myc B-cell lymphoma in vivo

artículo científico publicado en 2013

ATRA and the specific RARα agonist, NRX195183, have opposing effects on the clonogenicity of pre-leukemic murine AML1-ETO bone marrow cells.

artículo científico publicado en 2012

Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K

artículo científico publicado en 2010

Activity of trametinib in K601E and L597Q BRAF mutation-positive metastatic melanoma

artículo científico publicado en 2014

Adjuvant immunotherapy for cancer: the next step

artículo científico publicado en 2015

Adjuvant interferon in melanoma: is duration of therapy important?

artículo científico publicado en 2013

Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial

artículo científico publicado en 2008

Agonist immunotherapy restores T cell function following MEK inhibition improving efficacy in breast cancer

artículo científico publicado en 2017

An activating Pik3ca mutation coupled with Pten loss is sufficient to initiate ovarian tumorigenesis in mice

artículo científico publicado en 2012

An in vivo tumor model exploiting metabolic response as a biomarker for targeted drug development

artículo científico publicado en 2005

An open-label, two-arm, phase I trial of recombinant human interleukin-21 in patients with metastatic melanoma

artículo científico publicado en 2007

Applications of positron emission tomography in the development of molecular targeted cancer therapeutics

artículo científico publicado en 2003

Association of programmed death ligand-1 (PD-L1) expression with treatment outcomes in patients with BRAF mutation-positive melanoma treated with vemurafenib or cobimetinib combined with vemurafenib.

artículo científico publicado en 2017

Atypical melanocytic proliferations and new primary melanomas in patients with advanced melanoma undergoing selective BRAF inhibition

artículo científico publicado en 2012

BRAF Inhibition in BRAFV600E-Positive Anaplastic Thyroid Carcinoma.

artículo científico publicado en 2016

BRAF, a target in melanoma: implications for solid tumor drug development

artículo científico publicado en 2010

BRAF-targeted therapy and immune responses to melanoma

artículo científico publicado en 2013

BRAF/NRAS wild-type melanomas have a high mutation load correlating with histologic and molecular signatures of UV damage

artículo científico publicado en 2013

Bioinformatics pipelines for targeted resequencing and whole-exome sequencing of human and mouse genomes: a virtual appliance approach for instant deployment

artículo científico publicado en 2014

Biomarker analysis of on-treatment and at progression biopsies from BRIM7 - a phase 1B trial of combined vemurafenib and cobimetinib treatment in BRAF V600 mutated melanoma.

artículo científico publicado en 2014

CDK4 inhibitors an emerging strategy for the treatment of melanoma

Cell Cycle Regulation and Melanoma

artículo científico publicado en 2016

Cell cycle control as a promising target in melanoma

artículo científico publicado en 2015

Cell division and hematopoietic stem cells: not always exhausting

artículo científico publicado en 2005

Checkpoint inhibitors in melanoma and early phase development in solid tumors: what's the future?

artículo científico publicado en 2017

Clinical and biological efficacy of recombinant human interleukin-21 in patients with stage IV malignant melanoma without prior treatment: a phase IIa trial.

artículo científico publicado en 2009

Clinical and palliative care outcomes for patients of poor performance status treated with antiprogrammed death-1 monoclonal antibodies for advanced melanoma.

artículo científico publicado en 2017

Clinical and pathological associations of the activating RAC1 P29S mutation in primary cutaneous melanoma

artículo científico publicado en 2014

Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma

artículo científico publicado en 2010

Clinical features of serous retinopathy observed with cobimetinib in patients with BRAF-mutated melanoma treated in the randomized coBRIM study

artículo científico publicado en 2017

Clinical outcome and pathological features associated with NRAS mutation in cutaneous melanoma

artículo científico publicado en 2011

Clinical responses observed with imatinib or sorafenib in melanoma patients expressing mutations in KIT

artículo científico publicado en 2010

Clinicopathological characteristics associated with BRAF(K601E) and BRAF(L597) mutations in melanoma

artículo científico publicado en 2015

Clustered somatic mutations are frequent in transcription factor binding motifs within proximal promoter regions in melanoma and other cutaneous malignancies

artículo científico publicado en 2016

Clustered somatic mutations are frequent in transcription factor binding sites in melanoma and other cutaneous malignancies

article

Co-targeting deoxyribonucleic acid-dependent protein kinase and poly(adenosine diphosphate-ribose) polymerase-1 promotes accelerated senescence of irradiated cancer cells

artículo científico publicado en 2014

Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial

artículo científico publicado en 2016

Combination Anti-CTLA-4 and Anti-RANKL in Metastatic Melanoma

artículo científico publicado en 2014

Combination Therapies to Inhibit the RAF/MEK/ERK Pathway in Melanoma: We are not Done Yet

artículo científico publicado en 2015

Combination Therapy Targeting Ribosome Biogenesis and mRNA Translation Synergistically Extends Survival in MYC-Driven Lymphoma

artículo científico publicado en 2015

Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study

artículo científico publicado en 2018

Combination of vemurafenib and cobimetinib in patients with advanced BRAF(V600)-mutated melanoma: a phase 1b study

artículo científico publicado en 2014

Combined BRAF, MEK and CDK4/6 inhibition depletes intratumoral immune-potentiating myeloid populations in melanoma

scientific article published on 10 December 2020

Combined CDK4/6 and PI3Kα Inhibition Is Synergistic and Immunogenic in Triple-Negative Breast Cancer

artículo científico publicado en 2017

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

artículo científico publicado en 2015

Combined inhibition of PI3K-related DNA damage response kinases and mTORC1 induces apoptosis in MYC-driven B-cell lymphomas

artículo científico publicado en 2013

Combined vemurafenib and cobimetinib in BRAF-mutated melanoma

artículo científico publicado en 2014

Combining BET and HDAC inhibitors synergistically induces apoptosis of melanoma and suppresses AKT and YAP signaling

artículo científico publicado en 2015

Complete longitudinal analyses of the randomized, placebo-controlled, phase III trial of sunitinib in patients with gastrointestinal stromal tumor following imatinib failure

artículo científico publicado en 2012

Control of NF-kB activity in human melanoma by bromodomain and extra-terminal protein inhibitor I-BET151.

artículo científico publicado en 2014

Correlation of Ataxia-Telangiectasia-Mutated (ATM) gene loss with outcome in head and neck squamous cell carcinoma

article

Correlation of p16 status, hypoxic imaging using [18F]-misonidazole positron emission tomography and outcome in patients with loco-regionally advanced head and neck cancer

artículo científico publicado en 2014

Correlation of subjective self-reported melanoma growth rate with objective tumor proliferation markers

artículo científico publicado en 2008

Corrigendum to “Rechallenge with BRAF-directed treatment in metastatic melanoma: A multi-institutional retrospective study*” [Eur J Cancer 91 (2018) 116–124]

artículo científico publicado en 2018

Cyclin-dependent kinase 2 functions in normal DNA repair and is a therapeutic target in BRCA1-deficient cancers

artículo científico publicado en 2006

Dermatofibrosarcoma protuberans: a surgical disease with a molecular savior

artículo científico publicado en 2006

Dermatofibrosarcoma protuberans: recent clinical progress

artículo científico publicado en 2007

Desmoglein 2 promotes vasculogenic mimicry in melanoma and is associated with poor clinical outcome

artículo científico publicado en 2016

Differential (18)F-FDG and 3'-deoxy-3'-(18)F-fluorothymidine PET responses to pharmacologic inhibition of the c-MET receptor in preclinical tumor models

artículo científico publicado en 2011

Distinct clinical and pathological features are associated with the BRAF(T1799A(V600E)) mutation in primary melanoma

artículo científico publicado en 2006

Dysregulation of the basal RNA polymerase transcription apparatus in cancer

artículo científico

Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial

artículo científico publicado en 2006

Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy

artículo científico publicado en 2016

Efficacy of CHK inhibitors as single agents in MYC-driven lymphoma cells ⬇️

artículo científico publicado el 15 de agosto de 2011

Efficacy of anti-PD-1 therapy in patients with melanoma brain metastases.

artículo científico publicado en 2017

Expanded access programmes: patient interests versus clinical trial integrity

artículo científico publicado en 2014

Frequency of fibroblast growth factor receptor 1 gene amplification in oral tongue squamous cell carcinomas and associations with clinical features and patient outcome

artículo científico publicado en 2013

Future perspectives in melanoma research. Meeting report from the "Melanoma Bridge. Napoli, December 2nd-4th 2012".

artículo científico publicado en 2013

Gene Expression Profiling in BRAF-Mutated Melanoma Reveals Patient Subgroups with Poor Outcomes to Vemurafenib That May Be Overcome by Cobimetinib Plus Vemurafenib

artículo científico publicado en 2017

Gene expression profiling identifies activated growth factor signaling in poor prognosis (Luminal-B) estrogen receptor positive breast cancer

artículo científico publicado en 2009

Glucocorticoids did not reverse type 1 diabetes mellitus secondary to pembrolizumab in a patient with metastatic melanoma.

artículo científico publicado en 2016

Health Care Resource Utilization and Associated Costs Among Metastatic Cutaneous Melanoma Patients Treated with Ipilimumab (INTUITION Study).

artículo científico publicado en 2017

High-resolution MRI demonstrates that more than 90% of small intracranial melanoma metastases develop in close relationship to the leptomeninges

scientific article published on 01 March 2020

Host immunity contributes to the anti-melanoma activity of BRAF inhibitors

artículo científico publicado en 2013

Host immunity contributes to the anti-melanoma activity of BRAF inhibitors

artículo científico publicado en 2015

IL-21 induces in vivo immune activation of NK cells and CD8(+) T cells in patients with metastatic melanoma and renal cell carcinoma

artículo científico publicado en 2008

Imatinib as effective therapy for dermatofibrosarcoma protuberans: proof of concept of the autocrine hypothesis for cancer

artículo científico publicado en 2008

Immunotherapy of melanoma

scientific article published on 02 August 2016

Impact of MET expression on outcome in BRAF(V600E/K) advanced melanoma

artículo científico publicado en 2013

Improved survival with vemurafenib in melanoma with BRAF V600E mutation

artículo científico publicado en 2011

In vivo activity of combined PI3K/mTOR and MEK inhibition in a Kras(G12D);Pten deletion mouse model of ovarian cancer

artículo científico publicado en 2011

Incorporation of somatic BRAF mutation testing into an algorithm for the investigation of hereditary non-polyposis colorectal cancer

artículo científico publicado en 2007

Induced expression of c-fms in normal hematopoietic cells shows evidence for both conservation and lineage restriction of signal transduction in response to macrophage colony-stimulating factor.

artículo científico publicado en 1994

Inhibition of DNA-dependent protein kinase induces accelerated senescence in irradiated human cancer cells

artículo científico publicado en 2011

Inhibition of Mutated, Activated BRAF in Metastatic Melanoma

artículo científico publicado en 2010

Inhibition of Pol I transcription treats murine and human AML by targeting the leukemia-initiating cell population

artículo científico publicado en 2017

Inhibition of RNA polymerase I as a therapeutic strategy to promote cancer-specific activation of p53

scientific journal article

Inhibition of RNA polymerase I transcription initiation by CX-5461 activates non-canonical ATM/ATR signaling

artículo científico publicado en 2016

Integration of Immuno-Oncology and Palliative Care

artículo científico publicado en 2016

Ipilimumab in pretreated patients with unresectable or metastatic cutaneous, uveal and mucosal melanoma

artículo científico

KIT immunohistochemistry and mutation status in gastrointestinal stromal tumours (GISTs) evaluated for treatment with imatinib.

artículo científico publicado en 2006

Long term, continuous exposure to panobinostat induces terminal differentiation and long term survival in the TH-MYCN neuroblastoma mouse model

artículo científico publicado en 2016

Long-term outcome in BRAF(V600E) melanoma patients treated with vemurafenib: Patterns of disease progression and clinical management of limited progression

artículo científico publicado en 2015

Loss of CDKN2A expression is a frequent event in primary invasive melanoma and correlates with sensitivity to the CDK4/6 inhibitor PD0332991 in melanoma cell lines

artículo científico publicado en 2014

Low-dose cyclophosphamide enhances antigen-specific CD4+ T cell responses to NY-ESO-1/ISCOMATRIX™ vaccine in patients with advanced melanoma

article

MAD1 and c-MYC regulate UBF and rDNA transcription during granulocyte differentiation

artículo científico publicado en 2004

Marked, homogeneous, and early [18F]fluorodeoxyglucose-positron emission tomography responses to vemurafenib in BRAF-mutant advanced melanoma

artículo científico publicado en 2012

Melanoma

2015 article in Nature Reviews Disease Primers

Melanoma and immunotherapy bridge 2015 : Naples, Italy. 1-5 December 2015

artículo científico publicado en 2016

Melanoma staging: Evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual

artículo científico publicado en 2017

Melanoma: the intersection of molecular targeted therapy and immune checkpoint inhibition

artículo científico publicado en 2016

Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation

artículo científico publicado en 2010

Modulation of intratumoral hypoxia by the epidermal growth factor receptor inhibitor gefitinib detected using small animal PET imaging

artículo científico publicado en 2005

Molecular and clinical analysis of locally advanced dermatofibrosarcoma protuberans treated with imatinib: Imatinib Target Exploration Consortium Study B2225.

artículo científico publicado en 2005

Molecular targeting of dermatofibrosarcoma protuberans: a new approach to a surgical disease

artículo científico publicado en 2007

Molecular therapeutic advances in personalized therapy of melanoma and non-small cell lung cancer

artículo científico publicado en 2012

Molecularly targeted treatment for dermatofibrosarcoma protuberans

artículo científico publicado en 2004

Multi-tracer small animal PET imaging of the tumour response to the novel pan-Erb-B inhibitor CI-1033.

artículo científico publicado en 2006

Multiple Gastrointestinal Polyps in Patients Treated with BRAF Inhibitors

artículo científico publicado en 2015

Mutation analysis for systemic mastocytosis

Mutations in KIT occur at low frequency in melanomas arising from anatomical sites associated with chronic and intermittent sun exposure

artículo científico publicado en 2010

Navigating the challenge of tumor heterogeneity in cancer therapy

artículo científico publicado en 2014

Negative cell-cycle regulators cooperatively control self-renewal and differentiation of haematopoietic stem cells

artículo científico publicado en 2005

Novel combination therapies for BRAF-mutant melanoma

artículo científico publicado en 2015

Ocular toxicity in BRAF mutant cutaneous melanoma patients treated with vemurafenib

artículo científico publicado en 2014

Omitting radiosurgery in melanoma brain metastases: a drastic and dangerous de-escalation - Authors' reply

scientific article published on 01 August 2018

Optimizing combination dabrafenib and trametinib therapy in BRAF mutation-positive advanced melanoma patients: Guidelines from Australian melanoma medical oncologists.

artículo científico publicado en 2016

Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma.

artículo científico publicado en 2017

PIK3CA mutations associated with gene signature of low mTORC1 signaling and better outcomes in estrogen receptor-positive breast cancer

artículo científico publicado en 2010

Palbociclib synergizes with BRAF and MEK inhibitors in treatment naïve melanoma but not after the development of BRAF inhibitor resistance

artículo científico publicado en 2017

Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanoma

artículo científico publicado en 2013

Phase I Dose-Escalation and -Expansion Study of the BRAF Inhibitor Encorafenib (LGX818) in Metastatic BRAF-Mutant Melanoma

artículo científico publicado en 2017

Phase II study of the MEK1/MEK2 inhibitor Trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without a BRAF inhibitor

artículo científico publicado en 2012

Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma

artículo científico publicado en 2013

Phase III study of nilotinib versus best supportive care with or without a TKI in patients with gastrointestinal stromal tumors resistant to or intolerant of imatinib and sunitinib.

artículo científico publicado en 2012

Phenotype switching in melanoma: implications for progression and therapy

artículo científico publicado en 2015

Preclinical FLT-PET and FDG-PET imaging of tumor response to the multi-targeted Aurora B kinase inhibitor, TAK-901.

artículo científico publicado en 2013

Preclinical evaluation of nilotinib efficacy in an imatinib-resistant KIT-driven tumor model

artículo científico publicado en 2010

Primary Tumor Thickness is a Prognostic Factor in Stage IV Melanoma: A Retrospective Study of Primary Tumor Characteristics

artículo científico

Prognostic and predictive significance of plasma HGF and IL-8 in a phase III trial of chemoradiation with or without tirapazamine in locoregionally advanced head and neck cancer

artículo científico publicado en 2012

Prognostic significance of p16INK4A and human papillomavirus in patients with oropharyngeal cancer treated on TROG 02.02 phase III trial

artículo científico publicado en 2010

Prognostic significance of plasma osteopontin in patients with locoregionally advanced head and neck squamous cell carcinoma treated on TROG 02.02 phase III trial

artículo científico publicado en 2011

RAS mutations are associated with the development of cutaneous squamous cell tumors in patients treated with RAF inhibitors

artículo científico publicado en 2011

RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors

artículo científico publicado en 2012

Radiotherapy complements immune checkpoint blockade

artículo científico publicado en 2015

Randomized Trial of the Combination of Lomeguatrib and Temozolomide Compared With Temozolomide Alone in Chemotherapy Naive Patients With Metastatic Cutaneous Melanoma

artículo científico publicado en 2007

Randomized phase II study evaluating veliparib (ABT-888) with temozolomide in patients with metastatic melanoma

artículo científico publicado en 2015

Rate of growth in melanomas: characteristics and associations of rapidly growing melanomas

artículo científico publicado en 2006

Real-world treatment patterns and outcomes among metastatic cutaneous melanoma patients treated with ipilimumab

artículo científico publicado en 2017

Rechallenge with BRAF-directed treatment in metastatic melanoma: A multi-institutional retrospective study

artículo científico publicado en 2018

Recombinant NY-ESO-1 protein with ISCOMATRIX adjuvant induces broad integrated antibody and CD4+ and CD8+ T cell responses in humans

artículo científico publicado en 2004

Regulatory T-cell-mediated attenuation of T-cell responses to the NY-ESO-1 ISCOMATRIX vaccine in patients with advanced malignant melanoma

artículo científico publicado en 2009

Relationship between epidermal growth factor receptor status, p16(INK4A), and outcome in head and neck squamous cell carcinoma

artículo científico publicado en 2011

Reply to 'Comment on 'Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy''.

artículo científico publicado en 2017

Response of BRAF-mutant melanoma to BRAF inhibition is mediated by a network of transcriptional regulators of glycolysis

artículo científico publicado en 2014

Results of a randomized, double-blind phase II clinical trial of NY-ESO-1 vaccine with ISCOMATRIX adjuvant versus ISCOMATRIX alone in participants with high-risk resected melanoma

artículo científico publicado en 2020

Review: mucosal melanoma of the head and neck

artículo científico publicado en 2011

Safety and efficacy of combining ATRA with G-CSF in HSPC mobilization; a pilot study in multiple myeloma and non-Hodgkin's lymphoma patients

scientific article published on 06 August 2007

Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study

artículo científico publicado en 2014

Sentinel Lymph Node Biopsy in T4 Melanoma: An Important Risk-Stratification Tool

artículo científico

Sentinel node biopsy for melanoma: The medical oncology perspective

Splicing the way to leukemia with KIT

artículo científico publicado en 2008

Surrogate endpoints for overall survival in metastatic melanoma: a meta-analysis of randomised controlled trials

artículo científico publicado en 2014

Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib

artículo científico publicado en 2012

Survival of patients with advanced metastatic melanoma: The impact of novel therapies

artículo científico

Survival of patients with advanced metastatic melanoma: the impact of novel therapies-update 2017.

artículo científico publicado en 2017

Sustained clinical responses to tyrosine kinase inhibitor sunitinib in thyroid carcinoma

artículo científico publicado en 2008

Synergistic inhibition of ovarian cancer cell growth by combining selective PI3K/mTOR and RAS/ERK pathway inhibitors

artículo científico publicado en 2013

Targeted therapies for cutaneous melanoma

artículo científico publicado en 2014

Targeted-capture massively-parallel sequencing enables robust detection of clinically informative mutations from formalin-fixed tumours

artículo científico publicado en 2013

Targeting NRAS in melanoma

artículo científico

Targeting activating mutations of EZH2 leads to potent cell growth inhibition in human melanoma by derepression of tumor suppressor genes

artículo científico publicado en 2015

Targeting metabolic reprogramming as a potential therapeutic strategy in melanoma

artículo científico publicado en 2016

Targeting oncogenes in advanced melanoma

artículo científico publicado en 2012

Targeting oncogenic drivers and the immune system in melanoma

artículo científico publicado en 2012

Targeting the nucleolus for cancer-specific activation of p53.

artículo científico publicado en 2013

The Advantages and Challenges of Using FDG PET/CT for Response Assessment in Melanoma in the Era of Targeted Agents and Immunotherapy

artículo científico publicado en 2017

The best treatments to use after checkpoint inhibition in melanoma

The cell-cycle regulator CDK4: an emerging therapeutic target in melanoma

artículo científico publicado en 2013

The coming of age of MEK ⬇️

artículo científico publicado el 16 de julio de 2012

The current state of targeted therapy in melanoma: this time it's personal

artículo científico publicado en 2012

The drug vehicle and solvent N-methylpyrrolidone is an immunomodulator and antimyeloma compound

artículo científico publicado en 2014

The epigenetic regulator I-BET151 induces BIM-dependent apoptosis and cell cycle arrest of human melanoma cells.

artículo científico publicado en 2014

The genomic landscape of phaeochromocytoma

artículo científico publicado en 2015

The granulocyte-colony stimulating factor receptor (G-CSFR) interacts with retinoic acid receptors (RARs) in the regulation of myeloid differentiation

scientific journal article

The promise of PET in clinical management and as a sensitive test for drug cytotoxicity in sarcomas.

artículo científico publicado en 2008

The role of BRAF mutations in primary melanoma growth rate and survival

artículo científico publicado en 2015

The state of melanoma: challenges and opportunities

artículo científico publicado en 2016

The transcription cofactor c-JUN mediates phenotype switching and BRAF inhibitor resistance in melanoma

artículo científico publicado en 2015

The use of ipilimumab in patients with rheumatoid arthritis and metastatic melanoma

artículo científico publicado en 2016

Translational control of c-MYC by rapamycin promotes terminal myeloid differentiation

artículo científico publicado en 2008

Tumour mutation status and sites of metastasis in patients with cutaneous melanoma

artículo científico publicado en 2017

UBF levels determine the number of active ribosomal RNA genes in mammals

scientific journal article

UV-Associated Mutations Underlie the Etiology of MCV-Negative Merkel Cell Carcinomas

artículo científico publicado en 2015

Ubiquitous expression of the Pik3caH1047R mutation promotes hypoglycemia, hypoinsulinemia, and organomegaly.

artículo científico publicado en 2014

Updated efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in metastatic melanoma patients previously treated with anti-PD-1 therapy

artículo científico publicado en 2015

Updated results and correlative FDG-PET analysis of a phase IB study of vemurafenib and cobimetinib (MEK inhibitor [GDC-0973]), in advanced BRAFV600- mutated melanoma (BRIM7).

artículo científico publicado en 2014

Vemurafenib in metastatic melanoma patients with brain metastases: an open-label, single-arm, phase 2, multicentre study.

artículo científico publicado en 2016

Vemurafenib in patients with BRAFV600 mutation-positive metastatic melanoma: final overall survival results of the randomized BRIM-3 study

artículo científico publicado en 2017

Whole exome sequencing identifies a recurrent RQCD1 P131L mutation in cutaneous melanoma

artículo científico publicado en 2015

c-Myb is required for progenitor cell homeostasis in colonic crypts.

artículo científico publicado en 2007

coBRIM: a phase 3, double-blind, placebo-controlled study of vemurafenib versus vemurafenib + cobimetinib in previously untreated BRAFV600 mutation–positive patients with unresectable locally advanced or metastatic melanoma (NCT01689519)

article published in 2015

Dominio Público Uruguay está sostenido por:

Acerca de Dominio Público Uruguay

Ayuda